Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Sibutramine in Obese Hypertensive PatientsHazenberg B.P.
Albert Schweitzer Ziekenhuis, Lokatie Amstelwijk, Dordrecht, The Netherlands
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Objectives: To compare weight loss efficacy, safety and tolerability of sibutramine and placebo in mildly to moderately obese hypertensive subjects; to assess the effect of weight loss on blood pressure. Design: Randomized, double-blind, parallel-group; 3-week placebo run-in and 12-week treatment phase. Setting: Nine hospital outpatient clinics and general practices in the Netherlands. Participants: 127 men and women, 18–65 years old, with body mass indices (BMI) ranging from 27 to 40 kg/m2 and stabilized hypertension – mean resting diastolic blood pressure of 90–120 mm Hg – with or without antihypertensive medication. Interventions: Sibutramine 10 mg once daily; placebo. Main outcome measures: Body weight, blood pressure, routine laboratory and clinical safety monitoring. Results: Of 113 evaluable patients, 54 received sibutramine and 59 placebo. Weight reduction was significantly greater with sibutramine from week 2 onwards (last observation carried forward): mean, 4.4 kg with sibutramine and 2.2 kg with placebo (p = 0.002); mean percentage weight reduction, 4.7 and 2.3%, respectively (p < 0.001); mean BMI reduction, 1.6 and 0.8 kg/m2, respectively (p < 0.01). Reduction in excessive body weight was associated with a reduction in blood pressure in both groups, although the mean reduction in supine diastolic blood pressure was numerically, but not statistically significantly, greater in the placebo group (5.7 mm Hg) compared with the sibutramine group (4.0 mm Hg; p = 0.21). Similar reductions were seen in supine systolic blood pressure. Both treatments were well tolerated. Conclusions: Sibutramine 10 mg once daily is a useful, effective therapy for obesity in the presence of stable hypertension.
© 2001 S. Karger AG, Basel
Frohlich ED, Messerli FH, Reisin E, Dunn FG: The problem of obesity and hypertension. Hypertension 1983;5(suppl 3):III-71–III-78.
- Kannel WB, Brand N, Skinner JJJ, Dawber TR, McNamara PM: The relation of adiposity to blood pressure and development of hypertension. The Framingham Study. Ann Intern Med 1967;67:48–59.
- Witteman JCM, Willett WC, Stampfer MJ, Colditz GA, Sacks FM, Speizer FE, Rosner B, Hennekens CH: A prospective study of nutritional factors and hypertension among US women. Circulation 1989;80:1320–1327.
- Stamler R, Stamler J, Riedlinger WF, Algera G, Roberts RH: Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA 1978;240:1607–1610.
Benotti PN, Bistrian B, Benotti JR, Blackburn G, Forse RA: Heart disease and hypertension in severe obesity: The benefits of weight reduction. Am J Clin Nutr 1992;55(suppl 2):586S–590S.
- Drenick EJ, Fisler JS: Sudden cardiac arrest in morbidly obese surgical patients unexplained after autopsy. Am J Surg 1988;155:720–726.
- Singh RB, Rastogi SS, Singh DS, Mehta PJ: Effect of obesity and weight reduction in hypertension. Acta Cardiol 1990;45:45–56.
- Schmieder RE, Messerli FH: Obesity hypertension. Med Clin North Am 1987;71:991–1001.
Ramsay LE, Ramsay MH, Hettiarachchi J, Davies DL, Winchester J: Weight reduction in a blood pressure clinic. BMJ 1978;2:244–245.
- Schotte DE, Stunkard AJ: The effects of weight reduction on blood pressure in 301 obese patients. Arch Intern Med 1990;150:1701–1704.
MacMahon SW, Macdonald GJ, Bernstein L, Andrews G, Blacket RB: Comparison of weight reduction with metoprolol in treatment of hypertension in young overweight patients. Lancet 1985;i:1233–1236.
- Sonne-Holm S, Sørensen TIA, Jensen G, Schnohr P: Independent effects of weight change and attained body weight on prevalence of arterial hypertension in obese and non-obese men. BMJ 1989;299:767–770.
Dustan HP, Weinsier RL, James LD, Darnell BE, Hunter GR: Treatment of obesity hypertension. Circulation 1990;81:723.
Eliahou HE, Iaina A, Gaon T, Shochat J, Modan M: Body weight reduction necessary to attain normotension in the overweight hypertensive patient. Int J Obes 1981;5(suppl 1):157–163.
- MacMahon SW, Wilcken DEL, Macdonald GJ: The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986;314:334–339.
Lean MEJ: Sibutramine – a review of clinical efficacy. Int J Obes Relat Metab Disord 1997;21(suppl 1):S30–S36.
Stock MJ: Sibutramine: A review of the pharmacology of a novel anti-obesity agent. Int J Obes Relat Metab Disord 1997;21(suppl 1):S25–S29.
- Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB: Sibutramine produces dose-related weight loss. Obes Res 1999;7:189–198.
Wynne RD, Brown T, Braybrooke RM, Jones S, Stott DA, Thornton GM: An evaluation of the cardiovascular effects of sibutramine in normal volunteers (abstract P396). Int J Obes Relat Metab Disord 1995;19(suppl 2):144.
Liebowitz MT, Weinstein SP, McMahon FG: Sibutramine induces weight loss but not BP increase in obese hypertensive patients taking beta-blockers (abstract E045). Am J Hypertens 1998;11(4 pt 2):107A.
- Wing RR: Behavioral treatment of obesity. Its application to type II diabetes. Diabetes Care 1993;16:193–199.
- Dattilo AM, Kris-Etherton PM: Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. Am J Clin Nutr 1992;56:320–328.
- Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ: Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993;342:1076–1079.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.